While the OncoBEAMTM RAS CRC, known as a modified dPCR, diagnostic molecular testing based on BEAMing technology analyzed KRAS and NRAS oncogenic mutations synchronously with ultrasensitive analytical and diagnostic accuracy down to 0.02% mutant allelic fraction (MAF) [84, 94]. The gene discussed is KRAS; the disease is colorectal carcinoma.